An Interleukin-1 Signature in Breast Cancer Treated with Interleukin-1 Receptor Blockade: Implications for Treating Cytokine Release Syndrome of Checkpoint Inhibitors.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30217872.
- Also identified by DOI 10.1158/0008-5472.CAN-18-2225 and PMC identifier 6242808.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of <i>Cancer Research</i>, Wu and colleagues show that IL1b orchestrates tumor-promoting inflammation in breast cancer and can be targeted in patients using an IL1 receptor antagonist. <i>Cancer Res; 78(18); 5200-2. ©2018 AACR</i><i>See related article by Wu et al., p. 5243</i>.
Medical subject headings
- Breast Neoplasms
- Receptors, Interleukin-1